KROS vs. SLRN, ETNB, MIRM, TARS, CALT, OCS, ITOS, IDYA, ORIC, and MGTX
Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Acelyrin (SLRN), 89bio (ETNB), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Calliditas Therapeutics AB (publ) (CALT), Oculis (OCS), iTeos Therapeutics (ITOS), IDEAYA Biosciences (IDYA), ORIC Pharmaceuticals (ORIC), and MeiraGTx (MGTX). These companies are all part of the "medical" sector.
Keros Therapeutics (NASDAQ:KROS) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Keros Therapeutics presently has a consensus price target of $94.33, indicating a potential upside of 205.78%. Acelyrin has a consensus price target of $37.00, indicating a potential upside of 290.71%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Keros Therapeutics.
Acelyrin has lower revenue, but higher earnings than Keros Therapeutics.
Keros Therapeutics received 26 more outperform votes than Acelyrin when rated by MarketBeat users. However, 62.50% of users gave Acelyrin an outperform vote while only 60.78% of users gave Keros Therapeutics an outperform vote.
Acelyrin's return on equity of 0.00% beat Keros Therapeutics' return on equity.
In the previous week, Keros Therapeutics and Keros Therapeutics both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 1.81 beat Acelyrin's score of 0.76 indicating that Keros Therapeutics is being referred to more favorably in the media.
75.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 94.7% of Acelyrin shares are held by institutional investors. 28.0% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Keros Therapeutics and Acelyrin tied by winning 6 of the 12 factors compared between the two stocks.
Get Keros Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Keros Therapeutics Competitors List
Related Companies and Tools